Scholarlink

<p>This case report describes a 31-year-old woman with refractory systemic lupus erythematosus (SLE) and lupus nephritis (LN) who achieved clinical remission following a treatment regimen that included telitacicept, in combination with cyclosporine, hydroxychloroquine, and low-dose prednisone. Despite counseling on teratogenic risk and advice for contraception, an unplanned pregnancy occurred. Telitacicept was promptly discontinued upon pregnancy confirmation, and disease control was maintained with cyclosporine A and low-dose prednisone. Due to maternal hypothyroidism, a cesarean section was performed at 37⁺<sup>6</sup>&#xa0;weeks, delivering a healthy infant. At the 2-month follow-up, the infant was developing normally, had no history of unusual or severe infections, and had responded appropriately to routine vaccinations. No B-cell counts or immunoglobulin levels were assessed, which limits conclusions about immune function. This case highlights the critical importance of contraceptive adherence during telitacicept treatment and provides preliminary reassurance regarding pregnancy outcomes, though the lack of fetal pharmacokinetic data remains a limitation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of telitacicept in a refractory systemic lupus erythematosus patient with lupus nephritis and subsequent pregnancy: a case-based review

  • 期刊论文

  • 发表日期：

    2026年3月23日

查看全文
  • Jinhui Tan,
  • Hai Huang,
  • Linghua Tan,
  • Yuhuan Luo

摘要

This case report describes a 31-year-old woman with refractory systemic lupus erythematosus (SLE) and lupus nephritis (LN) who achieved clinical remission following a treatment regimen that included telitacicept, in combination with cyclosporine, hydroxychloroquine, and low-dose prednisone. Despite counseling on teratogenic risk and advice for contraception, an unplanned pregnancy occurred. Telitacicept was promptly discontinued upon pregnancy confirmation, and disease control was maintained with cyclosporine A and low-dose prednisone. Due to maternal hypothyroidism, a cesarean section was performed at 37⁺6 weeks, delivering a healthy infant. At the 2-month follow-up, the infant was developing normally, had no history of unusual or severe infections, and had responded appropriately to routine vaccinations. No B-cell counts or immunoglobulin levels were assessed, which limits conclusions about immune function. This case highlights the critical importance of contraceptive adherence during telitacicept treatment and provides preliminary reassurance regarding pregnancy outcomes, though the lack of fetal pharmacokinetic data remains a limitation.